Saterinone | CAS#102669-89-6 | PDE III inhibitor

MedKoo Cat#: 461842 | Name: Saterinone

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Saterinone is a phosphodiesterase (PDE) III inhibitor with additional alpha 1-blocking properties. It has vasodilating effects in patients with moderate to severe chronic heart failure.

Chemical Structure

Saterinone

CAS#102669-89-6

Theoretical Analysis

MedKoo Cat#: 461842

Name: Saterinone

CAS#: 102669-89-6

Chemical Formula: C27H30N4O4

Exact Mass: 474.2267

Molecular Weight: 474.56

Elemental Analysis: C, 68.34; H, 6.37; N, 11.81; O, 13.49

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Saterinone; Saterinonum; Saterinona;

IUPAC/Chemical Name

5-(4-(2-hydroxy-3-(4-(2-methoxyphenyl)piperazin-1-yl)propoxy)phenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile

InChi Key

KLEKLDFUYOZELG-UHFFFAOYSA-N

InChi Code

InChI=1S/C27H30N4O4/c1-19-24(15-21(16-28)27(33)29-19)20-7-9-23(10-8-20)35-18-22(32)17-30-11-13-31(14-12-30)25-5-3-4-6-26(25)34-2/h3-10,15,22,32H,11-14,17-18H2,1-2H3,(H,29,33)

SMILES Code

N#CC1=CC(C2=CC=C(OCC(O)CN3CCN(C4=CC=CC=C4OC)CC3)C=C2)=C(C)NC1=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 474.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kieback AG, Iven H, Stolzenburg K, Baumann G. Saterinone, dobutamine, and sodium nitroprusside: comparison of cardiovascular profiles in patients with congestive heart failure. J Cardiovasc Pharmacol. 1998 Oct;32(4):629-36. PubMed PMID: 9781932. 2: Kieback AG, Iven H, Stolzenburg K, Eichner E, Ruckdeschel W, Baumann G. Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure. Int J Cardiol. 2003 Oct;91(2-3):201-8. PubMed PMID: 14559131. 3: Zimmermann W, Scholz H, Schumacher C, Wenzlaff H, Haverich A. Effects of saterinone and its enantiomers R(+)-saterinone and S(-)-saterinone on the phosphodiesterase isoenzymes from ventricular tissue of failing human hearts and porcine hearts. Naunyn Schmiedebergs Arch Pharmacol. 1994 Jun;349(6):611-8. PubMed PMID: 7526225. 4: Szabó BM, van Veldhuisen DJ, van Dijk RB, Lahiri A, Mitrovic V, Stolzenburg K, Brouwer J, Lie KI. Hemodynamic and autonomic effects of intravenous saterinone in patients with chronic heart failure. J Cardiovasc Pharmacol. 1997 May;29(5):618-23. PubMed PMID: 9213204. 5: Rudolph M, Schmiedel G. Analysis of [14C]-saterinone and its metabolites in dog plasma, urine and bile by high-performance liquid chromatography with radioactivity and fluorescence detection and by mass spectrometry. J Pharm Biomed Anal. 1992 Apr;10(4):295-302. PubMed PMID: 1420459. 6: Iven H, Brasch H, Armah BI. Electrophysiologic effects of saterinone and milrinone in the isolated guinea pig myocardium. Arzneimittelforschung. 1988 Sep;38(9):1298-302. PubMed PMID: 2906246. 7: Armah BI, Hofferber E, Jacobitz P. Positive inotropic and vasodilatory actions of saterinone in vivo. Arzneimittelforschung. 1988 Sep;38(9):1303-9. PubMed PMID: 2906247. 8: Brunkhorst D, von der Leyen H, Meyer W, Schmidt-Schumacher C, Scholz H. Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium. Arzneimittelforschung. 1988 Sep;38(9):1293-8. PubMed PMID: 2852013. 9: Armah BI, Hofferber E, Stenzel W. Pharmacological properties of the positive inotropic and alpha 1-adrenoceptor blocking agent saterinone. Arzneimittelforschung. 1988 Sep;38(9):1287-92. PubMed PMID: 2906245. 10: Sridhara BS, Senior R, Anagnostou E, de La Motte S, Harrison FJ, Raftery EB, Lahiri A. Saterinone: A New Dual-Action Drug in the Acute Management of Chronic Heart Failure. Am J Ther. 1996 Aug;3(8):597-601. PubMed PMID: 11862296. 11: Armah BI, Muster D, Raap A, Brückner R, Graziadei I. Lack of stereoselectivity in the inotropic and phosphodiesterase inhibitory effects of saterinone enantiomers. Arzneimittelforschung. 1989 Nov;39(11):1384-92. PubMed PMID: 2559738. 12: Rudolph M. Direct enantiomeric separation of saterinone by high-performance liquid chromatography. J Chromatogr. 1990 Jan 26;525(1):161-8. PubMed PMID: 2338436. 13: Rudolph M, Volk D, Schmiedel G. Determination of saterinone enantiomers in plasma samples with an internal standard using a Chiralcel OD column, fractionation and reversed-phase chromatography. J Chromatogr. 1990 Dec 28;535(1-2):263-9. PubMed PMID: 2089055. 14: Ungerer M, Böhm M, Schwinger RH, Erdmann E. Antagonism of novel inotropic agents at A1 adenosine receptors and m-cholinoceptors in human myocardium. Naunyn Schmiedebergs Arch Pharmacol. 1990 Jun;341(6):577-85. PubMed PMID: 2392160. 15: von der Leyen H, Mende U, Meyer W, Neumann J, Nose M, Schmitz W, Scholz H, Starbatty J, Stein B, Wenzlaff H, et al. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations. Naunyn Schmiedebergs Arch Pharmacol. 1991 Jul;344(1):90-100. PubMed PMID: 1723153. 16: Rudolph M. Determination of saterinone in plasma by high-performance liquid chromatography. J Chromatogr. 1989 Dec 29;497:342-8. PubMed PMID: 2625472. 17: Schmitz W, Eschenhagen T, Mende U, Müller FU, Neumann J, Scholz H. Phosphodiesterase inhibition and positive inotropy in failing human myocardium. Basic Res Cardiol. 1992;87 Suppl 1:65-71. PubMed PMID: 1323266. 18: Bethke T, Meyer W, Schmitz W, Scholz H, Wenzlaff H, Armah BI, Brückner R, Raap A. High selectivity for inhibition of phosphodiesterase III and positive inotropic effects of MCI-154 in guinea pig myocardium. J Cardiovasc Pharmacol. 1993 Jun;21(6):847-55. PubMed PMID: 7687707.